Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. (Q53930659)

22 May 2018

title

Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. (English)

1 reference

22 May 2018

1 reference

A M Hoyumpa

1

1 reference

22 May 2018

H Trevino-Alanis

series ordinal

2

1 reference

22 May 2018

I Grimes

series ordinal

3

1 reference

22 May 2018

T J Humphries

series ordinal

4

1 reference

22 May 2018

publication date

1 April 1999

1 reference

22 May 2018

published in

Clinical Therapeutics

1 reference

22 May 2018

volume

21

1 reference

22 May 2018

issue

4

1 reference

22 May 2018

page(s)

691-701

1 reference

22 May 2018

The pharmacology of the gastric acid pump: the H+,K+ ATPase

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988320-4

7 January 2021

Helicobacter pylori: from bench to bedside

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988320-4

7 January 2021

Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988320-4

7 January 2021

The changing role of H2-receptor antagonists in acid-related diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988320-4

7 January 2021

Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988320-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988320-4

1 reference

7 January 2021

Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988320-4

7 January 2021

Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988320-4

7 January 2021

Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988320-4

7 January 2021

Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation*

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988320-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988320-4

7 January 2021

Effect of omeprazole on nocturnal intragastric pH in cirrhotics with inadequate antisecretory response to ranitidine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988320-4

7 January 2021

Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988320-4

7 January 2021

Clinical importance of hepatic cytochrome P450 in drug metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988320-4

7 January 2021

Clinical pharmacokinetics of lansoprazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988320-4

7 January 2021

Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988320-4

7 January 2021

10.1016/S0149-2918(00)88320-4

Identifiers

DOI

1 reference

22 May 2018

1 reference

22 May 2018